SXSW announces even more featured speakers joining the 2023 program

headed to texas

With three weeks left until game time, South by Southwest announced another long list of featured and keynote speakers. Photo via SXSW

Whether the return of South by Southwest (SXSW) in three weeks is putting butterflies in your tummy or sweat on your brow, we're in the home stretch. The newest announcement — another wave of featured speakers — does not say it's the final round, but time is running out to make adjustments before the start of the festival on March 10.

Previous announcements included keynote addresses from Patagonia CEO Ryan Gellert and team members who worked on the James Webb Space Telescope. There have also been two rounds of music showcase announcements, culminating in a list of nearly 500 performances.

The announcement on February 14 is heavy with big names including three entertainers presenting keynotes: actor, producer, and New York Times bestselling author Priyanka Chopra Jonas; Grammy Award-nominated singer-songwriter, producer, and author Margo Price; and Academy Award winner Tilda Swinton.

Two more newly announced keynote sessions come with longer descriptions: Chef José Andrés presents The Stories We Tell Can Change the World, and Bernard Sumner, Stephen Morris, and Gillian Gilbert of New Order appear in conversation with The Times rock & pop critic Will Hodgkinson.The former keynote tackles the responsibility of storytellers to address crises around the world, using Andrés' humanitarian group World Central Kitchen as a lens. The latter discusses the discography and history of the history-making band.

“Today's speaker announcement is a fantastic milestone for the 2023 event and spotlights five additional Keynotes and numerous Featured Speakers, including influential icons and up and coming innovators,” said Chief Programming Officer and Co-President Hugh Forrest. “We are extremely proud to have assembled a diverse, comprehensive conference program for SXSW, and we can’t wait to share it with our community in March.”

Organized into 25 programming tracks presented in a variety of session formats, SXSW celebrates the convergence of technology, film, television, and music. Tracks include civic engagement, climate change, design, film and TV, psychedelics, sports, travel, and more.

Just some featured speakers and sessions joining the 2023 lineup include:

  • Chair and CEO of General Motors Mary Barra with CEO, CTO, President, and co-founder of Cruise and co-founder of Twitch Kyle Vogt
  • Actress, philanthropist, entrepreneur, New York Times bestselling author, and co-founder of Hello Bello Kristen Bell, CEO of Hello Bello Erica Buxton, and actor, comedian, filmmaker, host of the podcast Armchair Expert, and co-founder of Hello Bello Dax Shepard
  • Chief Diversity Officer of TBWA\North America Aliah Berman with activist, advocate, author, and founder of the #MeToo Movement Tarana Burke
  • Founder and CEO of Joby Aviation Joe
  • Ben Bevirt with Chief Sustainability Officer at Delta Air Lines Pam Fletcher
  • Chief Digital and Commercial Officer at Unilever Conny Braams, President, Worldwide Advertising at Netflix Jeremi Gorman, founder and CEO of Media
  • Link Michael Kassan, and Senior Vice President and Chief Marketing and Communications Officer at Delta Air Lines Tim Mapes
  • Co-founder and President of OpenAI Greg Brockman with founder and CEO of Dot Dot Dot Media Laurie Segall
  • United States Secretary of Energy Jennifer M. Granholm
  • General Partner at Benchmark Bill Gurley with investor, New York Times bestselling author and host of the podcast The Tim Ferriss Show Tim Ferriss
  • The Art of Creating Influence 101 on navigating entertainment careers
  • The Blog Era: Hip-Hop's Wild Wild West on the influence of music bloggers
  • Daddy Issues in Film on fathers in film
  • Dateline 24/7: How the True Crime Powerhouse Became a Podcast Empire on a genre leader
  • Driving Personal Health Forward: The Role of Apple Watch and iPhone on digitally monitoring health at home
  • Evil Dead Rise: Flesh-Possessing Demons Come Home on the new Evil Dead film
  • An Inside Look at “Blindspotting” Season 2 with Rafael Casal and Daveed Diggs on the continuation of the series
  • Onyx Collective Presents “UnPrisoned” on a new Hulu series
  • The Kids Are (Not) Alright: Gun Violence Terrorizing Youth of America on activism and justice
  • Leguizamo Does America: Next Stop – Austin on the contributions of U.S. Latinos

For a full lineup and more information on featured sessions, visit SXSW.com.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings